BIOMARKER STRATEGIES FOR OPTIMIZING CHECKPOINT IMMUNOTHERAPY TREATMENT
April 17, 2019 | (1:00PM)
USA (United States of America)
This webinar will provide an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers. Checkpoint immunotherapy has proven to be a powerful therapeutic against a variety of cancers, yet due to response rates that range between 20 percent and 40 percent, esearchers and drug developers continue to seek ways to indicate response or non-response as early as possible.